



Journal Homepage: - www.journalijar.com
**INTERNATIONAL JOURNAL OF
 ADVANCED RESEARCH (IJAR)**

Article DOI: 10.21474/IJAR01/3039
 DOI URL: <http://dx.doi.org/10.21474/IJAR01/3039>



RESEARCH ARTICLE

SEX DIFFERENCES IN TRACE METALS AND DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS.

Vivek Kumar^{1,4}, Ajai Kumar², Jaya Prakash³, Varsha Gupta¹ and M Y Khan⁴

1. Rheumatology Laboratory, Department of Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kanpur.
2. Department of Biochemistry, Integral University, Lucknow.
3. Community Health Centre, Shivrajpur, Kanpur.
4. Department of Biotechnology, Baba Bhimrao Ambedkar University, Lucknow.

Manuscript Info

Manuscript History

Received: 30 November 2016
 Final Accepted: 28 December 2016
 Published: January 2017

Key words:-

Rheumatoid arthritis, trace minerals, superoxide dismutase, disease activity score

Abstract

Objectives: Rheumatoid arthritis (RA) is chronic autoimmune disease marked by tissue inflammation and joint destruction. Sex differences and essential element derangement in the incidences of RA are well described. **Methods:** The present study aims to determine serum mineral level, superoxide dismutase (SOD) activity and disease activity score (DAS) in female and male RA subjects and association of minerals with disease activity in both the sexes.

Results: Female RA patients had significantly reduced serum Zn as compared to male RA subjects. Females had non significantly low values for copper, magnesium and phosphorous as compared to male RA subjects. SOD and DAS were significantly increased in female RA subjects. The RA subjects had higher levels of serum zinc, copper and lower levels of serum Mg when compared with reference values. However none of them were found to be associated with disease activity.

Conclusions: The results suggest derangement of minerals in RA where mineral evaluation and supplementation especially of magnesium in RA patients would be helpful.

Copy Right, IJAR, 2016., All rights reserved.

Introduction:-

Rheumatoid arthritis (RA) is chronic inflammatory autoimmune disorder of unknown etiology affecting various symmetric joints of the body. Like other autoimmune diseases RA is also more prevalent in females as compared to males¹⁻⁴. Female to male ratio in RA is 3:1⁵. The differences in over occurrence and development of aggressive disease in females is not clear but genetic and hormonal factors are suggested to be involved⁶⁻¹¹.

Several observational studies suggest that women with RA have worst disease as compared to men¹²⁻¹⁶. In recent studies RA seems to have derangement of mineral content like Mg, Zn, Cu and P. Their optimum concentration is required for normal functioning of the body. However alterations in level of these trace minerals as Mg¹⁷, Zn¹⁸ and Cu (Copper) have been implicated in pathogenesis of RA as they are the co-factor of important enzymes involved in collagen and bone metabolism, the antioxidant defense system¹⁹ and the immune system²⁰. The development and progression of RA was suggested due to marginal deficiencies of Zn and Cu based on their

Corresponding Author:- Vivek Kumar and Varsha Gupta

Address:- Rheumatology Laboratory, Department of Biotechnology, Chhatrapati Shahu Ji Maharaj University, Kanpur.

serum levels^{21,22}. Many of these trace elements are present in bones as iron, copper, zinc, manganese, fluoride, strontium and boron²³. As the changes in the concentration of trace elements has been linked to inflammatory response therefore the present study was undertaken to analyze i) The concentration of Zn, Cu, Mg and P in female and male RA subjects along with activity of superoxide dismutase (SOD) and disease activity score (DAS-28-CRP). These may help in determination of possible roles of these in disease activity of female and male RA patients.

Materials and Methods:-

The study was started after approval from Institutional Ethical Committee and written informed consent was obtained from all the participants. 46 samples (31 females, 15 males) were randomly collected from the OPD of Orthopaedics from different centers during the study period. Patients were recruited with active RA who fulfilled 4 or above criteria of American College of Rheumatology (ACR)²⁴.

Clinically the patients presented symmetric arthritis with complaints of severe multiple joint pain along with morning stiffness (>1hr) of joint, presence of rheumatoid nodules along with radiographic changes like erosion, swelling (>3 joint especially phalanges), multiple joint involvement and deformity of peripheral joints (metacarpophalangeal (MCP) and proximal interphalangeal joint (PIP)) and decreased range of motion. The patients did not had any renal disease and were non hypertensive. Blood was drawn from overnight fasting patients for all the analysis.

Laboratory Analysis:-

The laboratory analysis for minerals was done by commercial kits from Coral clinical system (The Tulip group, India). Serum level of magnesium were estimated by Calmagite Method by using the UV- 1800 SHIMADZU UV Spectrophotometer at the wavelength of 510nm. Serum level of the Copper and Zinc were measured by colorimetric method by using the UV- 1800 SHIMADZU UV Spectrophotometer at the wavelength of 580nm, 570nm respectively. Serum Phosphorous level by Molybdate UV Method by using the UV- 1800 SHIMADZU UV Spectrophotometer at the wavelength of 340nm. SOD estimation was done according to Mishra and Fridovich, 1972²⁵. DAS-28 was measured according to counts of affected joint count and final value was calculated using CRP values.

Statistical Analysis:-

The data was analyzed with Student's independent t- test. The correlation of change in biochemical parameters was done by Pearson correlation analysis. A two-tailed ($\alpha=2$) $p<0.05$ was considered to be statistically significant. Graphpad Prism (version 3.0) and SPSS-15 were used for the analysis.

Results:-

The study was done on 46 RA patients (31 females and 15 males). There was no significant difference in the BMI of female and male patients. Female patients and male patients had significant difference in the mean age. They had reduced levels of serum zinc (131.48 μ mg/dl Vs 138.32 μ mg/dl $p<0.05$), serum copper (153.65mg/dl Vs 157.06mg/dl), serum magnesium (1.006mEq/l Vs 1.106mEq/l) and serum phosphorous (6mg/dl Vs 6.166mg/dl) as compared to male participants (table 1). Both female and male RA subjects had reduced levels of serum magnesium as compared to reference values. The activity of super oxide dismutase (SOD) and disease activity score (DAS-28-CRP) were significantly high in female patients as compared to males (table 1).

Intercorrelation between different parameters studied showed no correlation of any of the essential minerals tested with DAS-28-CRP or SOD in neither females (Table 2) nor males (table 3). However female patients showed significant negative correlation ($r=-0.434$; $p<0.05$) between phosphorous and copper (table 2).

Table 1:- shows the parameters analyzed in female and male subjects. P-phosphorous; SOD-Superoxide dismutase; DAS-28-CRP-Disease activity score-28-C-reactive protein.

| | Females N=31 | Males N=15 | Reference range |
|--------------------|-----------------|----------------|-----------------|
| Age | 33.60±1.817 | 43.53±2.74* | |
| BMI | 21.98±0.76 | 22.96±0.72 | |
| Zinc (*mg/dl) | 131.48±1.91 | 138.32±1.96* | 75-120*mg/dl |
| Copper(*mg/dl) | 153.65±3.47 | 157.066±2.46 | 70-140*mg/dl |
| Mg (mEq/l) | 1.006±0.686 | 1.71±0.051 | 1.3-2.5mEq/l |
| P (*mg/dl) | 6.006±0.147 | 6.11±0.1002 | 2.5-50(*mg/dl) |
| SOD (u/mg protein) | 1330.88±22.73 | 1024.60±53.91* | |
| DAS-28-CRP | 5.131±0.216 | 4.73±0.119 | |

Table 2:- Intercorrelation between different parameters in female RA patients. SOD-Superoxide dismutase. DAS-28-CRP-Disease activity score-28-C-reactive protein. * shows significant correlation (p<0.05).

| | Zinc | Copper | Magnesium | Phosphorous | SOD | DAS-28-CRP |
|-------------|--------|---------|-----------|-------------|--------|------------|
| Zinc | 1 | | | | | |
| Copper | -0.021 | 1 | | | | |
| Magnesium | -0.117 | -0.119 | 1 | | | |
| Phosphorous | 0.212 | -0.434* | 0.007 | 1 | | |
| SOD | -0.271 | 0.150 | -0.029 | -0.211 | 1 | |
| DAS-28-CRP | 0.098 | 0.256 | 0.077 | -0.215 | -0.139 | 1 |

*Significant values have p<0.05.

Table 3:- Intercorrelation between different parameters in male RA patients. SOD-Superoxide dismutase.

| | Zinc | Copper | Magnesium | Phosphorous | SOD | DAS-28-CRP |
|-------------|--------|--------|-----------|-------------|-------|------------|
| Zinc | 1 | | | | | |
| Copper | 0.105 | 1 | | | | |
| Magnesium | -0.252 | -0.252 | 1 | | | |
| Phosphorous | 0.260 | -0.457 | 0.04 | 1 | | |
| SOD | 0.232 | 0.105 | 0.138 | 0.422 | 1 | |
| DAS-28-CRP | 0.479 | -0.044 | 0.336 | 0.001 | 0.011 | 1 |

DAS-28-CRP-Disease activity score-28-C-reactive protein

Discussion:-

There was no significant difference in the BMI of female and male patients. Females have more aggressive and painful disease than males. As female patients in our study had less average age than males suggesting early onset of RA in them as compared to males. There are differences in functional capacity in female and male subjects with RA where females have more functional impairment than males²⁶. In our study also DAS-28-CRP is higher in females as compared to males. These differences may be due to general strength of bones and muscles, bone mineral density (BMD), hormones etc. However the widely used measure of function, the health assessment questionnaire (HAQ), is cross-sectionally higher (worse) in women²⁶.

In the present study, we found decreased level of serum magnesium in female and male RA subjects as compared to reference range, though no significant difference was observed between the two sexes in serum magnesium levels. Chronic inflammatory conditions in RA may alter the levels of magnesium and possible mechanism of reduced magnesium may be due to chronic inflammation and autoimmune injury^{17,27,28}. Our results are in accordance with^{17,27-29} suggesting that RA, is associated with serum magnesium disturbances²⁸. Mg is one of the essential nutrient of the body and studies suggest its role in reducing chronic inflammation³⁰. Decreased Mg level is considered as marker for RA¹⁷. Magnesium is an activator of sodium potassium ATPase, is antiarrhythmic and is associated with cardio vascular disease susceptibility³¹⁻³². Inflammation triggers its deficiency in animal models. In humans, low serum magnesium concentrations have been associated with high C-reactive protein (CRP) levels³³.

The level of phosphorous and copper was non-significantly higher in male RA patients as compared to females. In female RA patients, phosphorous showed inverse correlation with copper ($r = -0.434$; $p < 0.05$). There is strong association between elevated phosphorous and Ca and phosphorous products and the development of calciphylaxis. Phosphorous influences a number of pathways involved in vascular calcification. It also has a role in induction of differentiation of vascular smooth muscle cells into osteoblast-like cells capable of extracellular mineralization which is important process in development of vascular calcifications. Thus phosphorous may have a role in augmenting inflammation.

Both female and male RA patients had higher serum copper levels as compared to reference values. RA patients are shown to have high levels of copper^{34,35}. Their levels have been shown to increase in all inflammatory processes including RA. Ceruloplasmin, a copper containing enzyme is found to be significantly elevated in inflammatory conditions and has anti-inflammatory activity³⁶⁻³⁷. Our findings are consistent with Scudder et al 1978³⁸ and Tuncer et al 1999³⁹. Hypercuperemia associated with inflammatory response may be due to oxidative stress⁴⁰ as positive correlations were found between serum Cu levels and inflammatory markers as serum CRP and ESR in RA patients⁴¹. Yang et al, 2016⁴² have reported that RA patients living where farm soil has high copper had higher WBC count, ESR, DAS-28 and platelet count than people living in areas with low levels of copper. Cu is an environmental bioelement having key role in the cell's physiology. It is cofactor or component of the enzymes, participating in anti-oxidative processes, or in detoxification of oxygen free radicals. Cu complexes were effective in treating arthritis as Cu complexes have anti-inflammatory properties. Antiarthritic drugs in their active forms are complexed with copper³⁵. The hypercuperemia was also suggested to be the outcome of dyslipidemia⁴³ or inflammation, as the cytokines have been reported to enhance the release of Cu thioneins during the oxidative burst of polymorphonuclear cells⁴⁴. As many studies have reported higher levels of copper in active RA, therefore copper has been suggested to be used as an additional biochemical biomarker for RA⁴⁵.

In our study the levels of zinc were significantly higher in males as compared to females. This clearly shows that RA patients are not deficient in Zinc or copper¹⁹. However, Zoli et al., 1998⁴⁶ reported lower zinc levels in RA patients. As zinc is considered anti-inflammatory with studies showing negative correlation between zinc and levels of IL-1 β and TNF- α . Mierzecki et al, 2011¹⁸ have reported nonsignificant but higher levels of zinc in serum of RA patients. Though zinc levels should have been lower considering the role of proinflammatory cytokines as IL-1 and TNF- α which inhibit albumin synthesis in liver and lower their zinc-binding capacity, which should in turn reduce the plasma zinc levels. However lower values of zinc in other studies may be due to pharmacological treatments or other effects which also need to be considered. Serum zinc levels have been shown to decrease during acute-phase response of inflammation and with treatment with NSAIDs⁴⁴. Probably alterations in inflammation may have some role in the levels of essential minerals.

Inflammation may be the primary cause for systemic alterations in the levels of minerals and enzymes which further modulate acute phase plasma proteins⁴⁷. The study Chavan et al. 2015 by²⁹ have shown negative correlation between serum magnesium with TC, triglycerides, LDL-c and positive correlation with HDL-c. Thus lower serum magnesium may be associated with worsened lipid profile and increased CVD risk of RA patients.

In our study SOD activity is significantly increased in female RA patients as compared to males. The treatment of Methotrexate (for control of RA) has been reported to increase Zn-SOD activity in rats⁴⁸⁻⁴⁹.

Increased activity of SOD⁵⁰⁻⁵¹ may also be due to increased O₂⁻ production by hyperactive cells⁵²⁻⁵³. Higher SOD levels may be an after effect to nullify excessive free radical production. Post treatment the antioxidants are increased which lead to lower plasma MDA and increased total antioxidant capacity (TAC)^{54,55}.

RA is associated with serum mineral disturbances and oxidative stress. Our results show that male and female patients of RA neither differ much in copper, phosphorous and zinc levels nor the minerals are associated with DAS. Serum magnesium was lower in both sexes in RA subjects. Serum magnesium and serum copper may be useful biomarker for RA.

Compliance with Ethical Standards:-

Funding: This study was funded with grant numbers (BT/PR10980/GBD/27/134/2008 and 3/1/3/JRF-2009/MPD-66(34495)).

Ethical Approval: The study was approved by Institutional ethical committee and written informed consent was obtained from all the subjects.

References:-

1. Talal N: Sjögren's syndrome: historical overview and clinical spectrum of disease. *Rheum Dis Clin North Am* 1992, 18:507-515.
2. Linos A, Worthington JW, O'Fallon WM, Kurland LT: The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence and mortality. *Am J Epidemiol* 1980, 111:87-98.
3. Steen V, Conte C, Santoro D, et al.: Twenty-year incidence survey of systemic sclerosis (scleroderma). *Arthritis Rheum* 1980, 23:581-590.
4. Will R, Edmunds L, Elswood J, Calin A: Is there sexual inequality in ankylosing spondylitis? A study of 498 women and 1202 men. *J Rheumatol* 1990, 17:1649-1652.
5. Wolfe AM, Kellgren JH, Masi AT: The epidemiology of rheumatoid arthritis: a review. II. Incidence and diagnostic criteria. *Bull Rheum Dis* 1968, 19:524-529.
6. Van Vollenhoven RF, McGuire JL: Estrogen, Progesterone, and Testosterone: Can they be used to treat Autoimmune Diseases? *Cleveland Clinic J Med* 1994, 61:276.
7. Cutolo M, Villaggio B, Serio B, Montagna P, Capellino S, Straub RH, Sulli A: Synovial fluid estrogens in rheumatoid arthritis. *Autoimmun Rev* 2004, 3:193-198.
8. Wilder RL: Hormones, pregnancy, and autoimmune diseases. *Ann N Y Acad Sci* 1998, 840:45-50.
9. Cutolo M, Sulli A, Capellino S, Villaggio B, Montagna P, Serio B, Straub RH: Sex hormones influence on the immune system: basic and clinical aspects in autoimmunity. *Lupus* 2004, 13:635-638.
10. Olsen NJ, Kovacs WJ: Hormones, pregnancy, and rheumatoid arthritis. *J Gend Specif Med* 2002, 5:28-37.
11. O'Brien SM, Fitzgerald P, Scully P, Landers A, Scott LV, Dinan TG: Impact of gender and menstrual cycle phase on plasma cytokine concentrations. *Neuroimmunomodulation* 2007, 14:84-90.
12. Forslind K, Hafstrom I, Ahlmen M, Svensson B: Sex: a major predictor of remission in early rheumatoid arthritis? *Ann Rheum Dis* 2007, 66:46-52.
13. Tengstrand B, Ahlmen M, Hafstrom I: The influence of sex on rheumatoid arthritis: a prospective study of onset and outcome after 2 years. *J Rheumatol* 2004, 31:214-222.
14. Symmons DP: Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome. *Best Pract Res Clin Rheumatol* 2002, 16:707-722.
15. Kuiper S, van Gestel AM, Swinkels HL, de Boo TM, da Silva JA, van Riel PL: Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis. *J Rheumatol* 2001, 28:1809-1816.
16. Da Silva JA, Hall GM: The effects of gender and sex hormones on outcome in rheumatoid arthritis. *Baillieres Clin Rheumatol* 1992, 6:196-219.
17. Lucia M, Isabela S, Minerva G. Changes of serum magnesium level in patients with rheumatoid arthritis stage I-II, before treatment. *Med Con* 2011; 6:9-16.
18. Mierzecki A, Strecker D, Radomska K. A pilot study on zinc levels in patients with Rheumatoid arthritis *Biol Trace Elem Res* 2011; 143:854-862.
19. Milanino R, Frigo A, Bambara LM et al. Copper and zinc status in rheumatoid arthritis: studies of plasma, erythrocytes and urine, and their relationship with disease activity markers and pharmacological treatment. *Clin Exp Rheumatol* 1993; 11: 271-81.
20. Stabel JR, Spears JW. Effect of copper on immune function and disease resistance. *Adv Exp Med Biol* 1989; 258:243-52.
21. Simkin PA. Oral zinc sulphate in rheumatoid arthritis. *Lancet* 1976;2:539-42.
22. Rainsford KD. Environment ion perturbations, especially as they affect copper status, are a factor in the etiology of arthritis conditions: an hypothesis. In: Sorenson JRJ, editor. *Inflammatory disease and copper*. Clifton, NJ, Humana Press; 1982. pp. 137-43.
23. Sandstead HH, Penland JG, Alcock NW, Dayal HH et al Effects of repletion with zinc and other micronutrients on neuropsychologic performance and growth of Chinese children. *Am J Clin Nutr* 1998; 68:470-55.
24. Arnett FC, Edworthy SM, Bloch DA, Mc Shane, DJ, Fries JF, Cooper NS et al. The American Rheumatism Association 1987 revised criteria for the classification of Rheumatoid arthritis. *Arthritis Rheum* 1988; 31:315-24.
25. Misra, H.P., and Fridovich, I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. *J. Biol. Chem.* 1972; 247:188.
26. van Vollenhoven RF Sex differences in rheumatoid arthritis: more than meets the eye...*BMC Medicine* 2009, 7:12.
27. Amin RS, Adallah FR, Abdel-Hamid NM. Variations in some. Blood minerals related to bone remodeling and haematopoiesis in rheumatoid arthritis. Abstracts of The IXth International Convention of Polish Magnesium Society "Contemporary directions in researches on elements" Kazimierz Dolny upon Wisla, Poland 9th -12th September, 2004. *Magnesium Research*. 2005; 18(2):135-40. [Magnesium Research. 18(2); 135-40, June 2005, ABSTRACTS]

28. Cortes YE, Moses L. Magnesium disturbances in critically ill patients. *Compend Contin Educ Vet.* 2007;29(7):420-27.
29. Chavan VU, Ramavataram DVSS, Patel PA, Rupani MP. Evaluation of serum magnesium, lipid profile and various biochemical parameters as risk factors of cardiovascular diseases in patients with rheumatoid arthritis. *J Clin Diag Res* 2015; 9: BC01-BC05.
30. Weisinger JR, Bellorin-Font E. Magnesium and phosphorus. *Lancet* 1998; 352:391-96.
31. Chiuvè SE, Korngold EC, Januzzi Jr. JL, Gantzer ML, Albert CM. Plasma and dietary magnesium and risk of sudden cardiac death in women. *Am J Clin Nutr* 2011; 93:253-60.
32. Makhdoom A, Rahopoto MQ, Laghari MA, Qureshi Pir AL, Siddiqui KA. Bone mineral levels in rheumatoid arthritis. *Medical Channel* 2009; 15:99-102.
33. Rodríguez-Morán M, Guerrero-Romero F. Serum magnesium and C-reactive protein levels. *Arch Dis Child* 2008; 93:676-80.
34. Jacobson DM. Corinthian bronze and the gold of alchemists. *Gold Bulletin.* 2000;33(2):60-66.
35. Rainsford KD. Environment ion perturbations, especially as they affect copper status, are a factor in the etiology of arthritis conditions: an hypothesis. In: Sorenson JRJ, editor. *Inflammatory disease and copper.* Clifton, NJ, Humana Press 1982; pp. 137-43.
36. Milanino R, Marrella M, Gasperini R, Pasqualicchio M, Velo G. Cu and Zn body levels in inflammation: an overview of the data obtained from animal and human studies. *Agents Actions.* 1983;39:195-209.
37. Gubler CJ, Lahey ME, Cartwright GE, Wintrobe MM. Studies on copper metabolism. IX. Transportation of copper in blood. *Jour. Clin. Investigations.* 1953;32:405-14.
38. Scudder PR, Al-Timimi D, McMurray W, White AG, Zoob BC, Dormandy TL. Serum copper and related variables in rheumatoid arthritis. *Ann. Rheum. Dis* 1978; 37: 67-70.
39. Tuncer S, Kamanli A, Akcil E, Kavas GO, Seckin B, Atay MB. Trace element and magnesium levels and superoxide dismutase activity in rheumatoid arthritis. *Biol. Trace Element Res* 1999; 68:137-142.
40. Ford ES. Serum copper concentrations and coronary heart disease among US adults. *Am J Epidemiol* 2000; 151:1182-8.
41. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. *N Engl J Med* 1994; 331: 417-24.
42. Yang TH, Yuan TH, Hwang YH, Lian LB, Meng M, Su CC. Increased inflammation in rheumatoid arthritis patients living where farm soils contain high levels of copper. *J Formosan Med Ass* 2016; 115: 991-996.
43. Aaseth J, Munthe E, Forre O, Steinnes E. Trace elements in serum and urine of patients with rheumatoid arthritis. *Scand J Rheumatoid* 1978; 7: 237-40.
44. Balogh Z, El-Ghobarey AF, Fell GS, Brown DH, Dunlop J, Dick WC. Plasma zinc and its relationship to clinical symptoms and drug treatment in rheumatoid arthritis. *Ann Rheum Dis* 1980; 39:329 – 332.
45. Chakraborty M, Chutia H, Changkakati R. Serum Copper as a Marker of Disease Activity in Rheumatoid Arthritis *Journal of Clinical and Diagnostic Research.* 2015 Dec, Vol-9(12): BC09-BC11.
46. Zoli A, Altomonte L, Caricchio R et al. Serum zinc and copper in active rheumatoid arthritis: correlation with interleukin 1 β and tumour necrosis factor α . *Clin Rheumatol* 1998; 17:378-382.
47. Dean C. *The magnesium miracle.* 1st edn. New York: Ballantine Books (an imprint of the Random House Publishing Group. Inc.). 2007; pp. 1-400.
48. Armagan A, Uzar E, Uz E, Yilmaz HR, Kutluhan S, Koyuncuoglu HR, Soyupek S, Cam H, Serel TA. Caffeic acid phenethyl ester modulates methotrexate-induced oxidative stress in testes of rat. *Hum Exp Toxicol* 2008; 27:547-552.
49. Al-Saleh E, Al-Harmi J, Nandakumaran M, Al-Shammari M, Al-Jassar W. Effect of methotrexate administration on status of some essential trace elements and antioxidant enzymes in pregnant rats in late gestation. *Gynecol Endocrinol* 2009; 25:816-822.
50. Vijayakumar D, Suresh K. Lipid peroxidation and antioxidant status in blood of rheumatoid. *Indian Journal of Clinical Biochemistry* 2006; 21 (1) 104-108.
51. Cimen MY, Cimen OB, Kaçmaz M, Oztürk HS, Yorgancıoğlu R, Durak I. Oxidant/antioxidant status of the erythrocytes from patients with rheumatoid arthritis. *Clin Rheumatol* 2000; 19: 275-277.
52. Gregory E M, Fridovich I. Induction of superoxide dismutase by molecular oxygen. *J Bacteriol* 1973; 114: 543-8.
53. Hassan H M, Fridovich I. Regulation of the synthesis of superoxide dismutase in *Escherichia coli*: induction by methyl viologen. *J Biol Chem* 1977; 252: 7667-72.
54. Jaswal S, Mehta HC, Sood AK, Kaur J. Antioxidant status in rheumatoid arthritis and role of antioxidant therapy. *Clin Chim Acta.* 2003; 338:123-129.
55. Nourmohammadi I, Athari-Nikazm S, Vafa MR, Bidari A, Jazayeri S, Hoshyarrad A et al., Effect of antioxidant supplementations on oxidative stress in rheumatoid arthritis patients. *J Biol Sci* 2010; 10: 63-66.